Filter Results:
(3,405)
Show Results For
- All HBS Web
(3,405)
- People (9)
- News (719)
- Research (2,190)
- Events (38)
- Multimedia (28)
- Faculty Publications (1,290)
Show Results For
- All HBS Web
(3,405)
- People (9)
- News (719)
- Research (2,190)
- Events (38)
- Multimedia (28)
- Faculty Publications (1,290)
- 01 Jun 1996
- News
GMAT Added to Admissions Criteria
In April, Dean Kim B. Clark announced that Harvard Business School will add the Graduate Management Admissions Test (GMAT) to the portfolio of criteria used to evaluate a candidate's application to the MBA Program, effective for... View Details
- 2023
- Working Paper
Market Exclusivity and Innovation: Evidence From Antibiotics
By: Edward Kong and Olivia Zhao
The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details
Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States
Kong, Edward, and Olivia Zhao. "Market Exclusivity and Innovation: Evidence From Antibiotics." Working Paper, December 2023.
- 31 Jan 2016
- News
Studios Back App, Hoping to Fill Cinema Seats
to keep testing it,” said Mr. Bakal, adding that variable pricing won't be among the company’s offerings when it launches nationwide. Atom Tickets has been operating in three test markets since April, where... View Details
- 23 Jan 2019
- News
The Promise of Personalized Medicine
be able to do computational prediction for creating a top 20 list of antisense oligos. With those, we can test them against his cell line. So as part of the biopsy, in phase one, we establish a cell line. What that is, is it’s taking... View Details
- 2008
- Chapter
Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation
By: Arthur A. Daemmrich
A consumer-oriented model for drug development and use has attracted attention in recent years as an alternative to the much-maligned approach of mass-marketing blockbuster drugs. In a parallel development, patients and disease-based organizations have assumed greater... View Details
Keywords: Geographic Location; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Demand and Consumers; Pharmaceutical Industry; European Union; Germany; United States
Daemmrich, Arthur A. "Where is the Pharmacy to the World? Pharmaceutical Industry Location and International Regulatory Variation." Chap. 16 in Ways of Regulating: Therapeutic Agents between Plants, Shops, and Consulting Rooms. Vol. 363, edited by Jean Paul Gaudillière and Volker Hess, 271–290. Berlin, Germany: Max-Planck-Institut für Wissenschaftsgeschichte, 2008.
- Web
Frequently Asked Questions | MBA
Frequently Asked Questions MD / MBA If I am interested in pursuing the MD/MBA Program, when do I apply? When should I take the GMAT or GRE? Is one test preferred over the other? Is there a target test score?... View Details
- Profile
Mike Monagle
business and then moved into a strategic role managing company interests in Asia. As it became clearer that Mike wanted to build a business of his own, he recognized a need to expand his skills and “reflect on my future,” he says. “In the right program, I could View Details
- Web
Success Academy Charter Schools | Information Technology
Development and Research test caption Previous test caption Previous Next test caption Previous Next More Featured Cases The Reinvention of Kodak Professor Ryan Raffaelli, Dave... View Details
- Web
Admissions Resources - Doctoral
letters, and suggestions on how to identify and approach your recommenders. Standardized Tests As you prepare for your PhD application, watch this video to learn more about what standardized tests are... View Details
- 12 Aug 2019
- Working Paper Summaries
Case Histories of Significant Medical Advances
- Article
Use of Connected Digital Products in Clinical Research Following the COVID-19 Pandemic: A Comprehensive Analysis of Clinical Trials
By: Caroline Marra, William J. Gordon and Ariel Dora Stern
Objectives: In an effort to mitigate COVID-19 related challenges for clinical research, the U.S. Food and Drug Administration (FDA) issued new guidance for the conduct of ‘virtual’ clinical trials in late March 2020. This study documents trends in the use of... View Details
Keywords: Connected Digital Products; Telehealth; Remote Monitoring; Health Testing and Trials; Research; Governing Rules, Regulations, and Reforms; Information Technology
Marra, Caroline, William J. Gordon, and Ariel Dora Stern. "Use of Connected Digital Products in Clinical Research Following the COVID-19 Pandemic: A Comprehensive Analysis of Clinical Trials." BMJ Open 11, no. 6 (2021).
- March 2015 (Revised January 2024)
- Case
CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen (HBS MBA ’01) hoped to win over a prominent venture capital investor for Series B financing of his firm CVI that was creating a drug-eluting balloon (DES) to treat peripheral arterial disease. As a second-mover, Duke felt he was more likely to acquire... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (A): How to Evaluate the Commercial Viability of New Health Care Technologies." Harvard Business School Case 315-045, March 2015. (Revised January 2024.)
- 23 Aug 2020
- News
In the UK, She Leads the Search for a COVID Vaccine
Kate Bingham (MBA 1991) Kate Bingham (MBA 1991) When she was asked to chair the UK’s Vaccine Taskforce back in May, Kate Bingham (MBA 1991) paused. Despite nearly three decades of experience as a life sciences investor with SV Health Investors, the enormity of leading... View Details
- September 1991 (Revised August 1994)
- Background Note
Note on Pharmaceutical Industry Regulation
Traces the evolution of U.S. regulatory policy towards the pharmaceutical industry over the course of the twentieth century. A major theme is the steady shift away from a policy of 'let the buyer beware' to the creation of a complex and time-consuming review process,... View Details
Keywords: Safety; Industry Growth; Marketing; Research and Development; Health Testing and Trials; Economics; Pharmaceutical Industry; United States
Emmons, Willis M., III. "Note on Pharmaceutical Industry Regulation." Harvard Business School Background Note 792-002, September 1991. (Revised August 1994.)
- 15 Dec 2024
- News
After Ozempic
Back before Ozempic, when Kate Mulroney (MBA 1984) spoke at technical conferences about her work at Novo Nordisk, people often assumed she was talking about Novartis. “I’d have to explain that’s a Swiss company; we’re Danish,” says Mulroney, now head of advanced... View Details
- 01 Sep 2017
- News
Starting Lineup: Power Plays
one-third of the US energy supply. Won a $5.3 million grant from the Department of Energy to test its Triton-C “wave energy converter” at a Navy test site in Kaneohe Bay, Hawaii. Energicity Cofounder and CEO... View Details
- March 2015 (Revised February 2022)
- Supplement
CV Ingenuity (B): Epilogue
By: Regina E. Herzlinger and Andrew Otazo
Duke Rohlen used a lea-nfunding, iconoclastic strategy for his start up for a drug eluding balloon for peripheral artery disease. His giant competitors were first movers. Did Duke obtain the funding he sought? How did his DEB fare versus that of his competitors?
The... View Details
Keywords: CV Ingenuity; CVI; Drug Eluting Balloon; DEB; Drug Eluting Stent; Angioplasty Balloon; FoxHollow; Medical Device; Medical Device Startup; Premarket Approval; PMA; Lutonix; Stellarex; LEVANT; ILLUMENATE; Clinical Trials; Peripheral Arterial Disease; PAD; Healthcare Startups; Covidien; Health Care and Treatment; Health Testing and Trials; Business Startups; Commercialization; Strategy; Health Industry; Medical Devices and Supplies Industry; United States; Europe
Herzlinger, Regina E., and Andrew Otazo. "CV Ingenuity (B): Epilogue." Harvard Business School Supplement 315-087, March 2015. (Revised February 2022.)
- 01 May 2020
- News
How Everlywell Pulled Off Its COVID-19 Pivot in Two Weeks
- Web
Tools | New Venture Competition
Starting a Social Enterprise Experts from Foley Hoag LLP address high level legal issues that New Venture Competition business plan entrants might have, and practical advice for starting a business. Legal Aspects of Starting a Social Enterprise, Powerpoint Deck... View Details